Core Viewpoint - The medical beauty platform, New Oxygen (Nasdaq: SY), reported a decline in performance for the second quarter of 2025, with total revenue of 379 million yuan, a year-on-year decrease of 7%, and a net loss of 36 million yuan, compared to a profit of 18.9 million yuan in the same period last year. The revenue drop is attributed to a decrease in the number of medical service providers subscribing to the platform [2][4]. Group 1: Financial Performance - New Oxygen's revenue from medical beauty treatment services surged by 426.1% year-on-year to 144 million yuan, becoming the largest source of income for the company [2]. - The information and booking services segment continued to face pressure, with revenue of 135.2 million yuan, a decline of 35.6% compared to 209.7 million yuan in the same quarter of 2024 [4]. - The overall medical beauty market in China reached 280.4 billion yuan in 2023, with expectations to grow to 381.6 billion yuan by 2025, attracting significant interest from major internet companies [6][7]. Group 2: Business Transformation - New Oxygen is transitioning from a traditional B2B information intermediary model to a B2C vertical integrator in the medical beauty industry, facing intense competition [3]. - The company has established 29 operational chain stores in major cities, with 25 centers achieving positive monthly cash flow [5]. - The CEO anticipates that the medical beauty industry will see a significant increase in the number of chain stores, aiming for a thousand-store scale within 8 to 10 years [6]. Group 3: Industry Challenges and Opportunities - The medical beauty industry is experiencing dual challenges of intensified competition and rising consumer expectations, with platforms like Alibaba Health and Meituan diversifying their offerings [4][8]. - The CEO emphasizes that the core issue in the industry is a surplus of demand but a shortage of quality supply, presenting a key opportunity for New Oxygen's expansion [6]. - The industry is expected to undergo a transformation towards a "mass medical beauty" era as product prices normalize and quality supply increases, which will enhance the overall trust in the industry [6][9]. Group 4: Competitive Landscape - Major players like JD Health and Alibaba are actively entering the medical beauty space, with JD Health launching its first self-operated offline clinic and Alibaba creating a service matrix leveraging its ecosystem [7]. - The competition is shifting towards a model where online platforms dominate while offline services require a diverse approach, focusing on quality and customer experience [8]. - The industry is entering a phase of strong regulation, with new standards and policies being implemented to promote development and compliance [9].

Summary of So-Young's Q2 2025 Earnings Call Company Overview - **Company**: So-Young International Inc - **Industry**: Medical Aesthetics Key Financial Performance - Q2 2025 total revenue reached **RMB 379 million**, with aesthetic center revenue at **RMB 144 million**, marking a strategic shift as the largest revenue segment for the first time [2][3] - Total revenues decreased by **7% year-over-year** to **RMB 378.7 million**, primarily due to a decline in information service revenues [2][15] - Aesthetic treatment service revenues soared by **426.1% year-over-year** to **RMB 144.4 million** [15] - Net loss recorded at **RMB 36 million**, compared to a net income of **RMB 18.9 million** in the same period last year [16] Operational Highlights - Aesthetic center business saw a **46% quarter-over-quarter** and **426% year-over-year** revenue increase, driven by expansion to **29 centers** [2][4] - Over **100,000 active users** and **67,400 verified treatment visits** in Q2, up **24% quarter-over-quarter** and **381% year-over-year** [4] - High repeat purchase rate exceeding **60%** and customer satisfaction score of approximately **five out of five** [5] Strategic Initiatives - New treatments launched in Q2 2025 include **Miracle PLLA**, **Mermaid Skin Booster**, and **BBL Hero**, enhancing the product portfolio and increasing average revenue per user (ARPU) [2][9] - Customer acquisition strategies focus on cost efficiency, with over **70% of new clients** coming from existing customers [7][21] - Plans to open around **ten new aesthetic centers** in Q3 2025, aiming for a total of **50 centers** by the end of the year [11][17] Quality Assurance and Service Delivery - Rigorous physician selection and standardized training ensure high service quality, with nearly **90% of doctors** being specialist dermatologists [6][24] - Digitalization and AI-driven solutions enhance transparency and traceability in medical experiences [6] Market Outlook - The light medical aesthetic market in China is expected to reach around **RMB 340 billion** by 2030, with So-Young targeting a **25% market share** [20] - Current penetration in China is below **5%**, indicating substantial growth potential compared to mature markets like South Korea [20] Future Expansion Plans - Long-term goal to achieve **1,000 centers** within **8-10 years**, with a phased approach to expansion [18][19] - Plans to pilot **two to three franchise centers** in Q4 2025, with future expansion pace dependent on pilot performance [19] Cost Structure and Efficiency - Average customer acquisition cost remains low, with a focus on private domain traffic and referrals [21] - R&D expenses decreased by **26.6%** to **RMB 31.2 million**, attributed to improved staff efficiency [14] Product Strategy - Focus on anti-aging treatments and a curated product portfolio to drive repeat business and positive referrals [26][27] - Plans to introduce new light-based treatments and injectable products, enhancing the product pipeline [22][23] Conclusion So-Young's strategic shift towards aesthetic centers has resulted in significant revenue growth, despite overall revenue declines in other segments. The company is well-positioned for future expansion in the rapidly growing medical aesthetics market in China, with a focus on quality service delivery, customer acquisition efficiency, and a robust product portfolio.

Core Viewpoint - New Oxygen Technology is undergoing a strategic transformation amid a slowdown in online traffic and increasing regulation in the medical beauty industry, resulting in a decline in overall revenue and a shift towards offline business growth [1][2]. Financial Performance - In Q2, New Oxygen's total revenue decreased by 7.0% year-on-year to 379 million yuan, with a net loss of 36 million yuan compared to a profit of 18.9 million yuan in the same period last year [3][4]. - Revenue from information and appointment services, a core business, fell by 35.6% to 135 million yuan, indicating intensified competition and regulatory pressures in the online medical beauty service market [3][4]. - Revenue from medical product sales and maintenance services dropped by 28.1% to 76 million yuan, attributed to reduced order volumes and market demand changes [3][4]. Business Transformation - New Oxygen's offline light medical beauty chain business has seen explosive growth, with revenue from medical treatment services soaring by 426.1% year-on-year to 144 million yuan, becoming the largest revenue source for the company [1][4]. - The CEO expressed optimism about the offline business, indicating a significant structural breakthrough in the company's strategic transformation [1][6]. Expansion Plans - As of June 30, 2025, New Oxygen operates 29 light medical beauty chain stores in nine major cities, with plans to expand to 50 stores by the end of 2025 [6][7]. - The company aims to achieve a scale of 1,000 stores within 8 to 10 years, reflecting confidence in the long-term potential of the light medical beauty chain business [5][7]. - The management plans to pilot 2 to 3 franchise stores in Q4 2025, indicating a potential shift towards a franchise model in the future [8]. Market Challenges - Despite the growth in offline business, New Oxygen faces challenges from increasing competition in the light medical beauty market, with more participants entering the field [8][9].

Core Viewpoint - New Oxygen Technology is undergoing a significant strategic transformation amid a slowdown in online traffic and increasing regulation in the medical beauty industry, with a notable shift from online services to offline light medical beauty chain operations [1][2]. Financial Performance - In Q2, New Oxygen reported total revenue of 379 million yuan, a year-on-year decline of 7.0% [3]. - The company experienced a net loss of 36 million yuan in Q2, compared to a profit of 18.9 million yuan in the same period last year [4]. - Revenue from information and appointment services, a core business, fell by 35.6% to 135 million yuan, indicating intensified competition and regulatory pressures [3][4]. Business Transition - New Oxygen's offline light medical beauty chain business saw a remarkable growth of 426.1% in revenue, reaching 144 million yuan, becoming the largest revenue source for the company [1][6]. - The company plans to expand its "New Oxygen Youth Clinic" brand across China, aiming for a thousand-store scale in 8 to 10 years [6][7]. Operational Strategy - The management emphasizes a self-operated model for new stores, which allows for controlled capital expenditure and shorter payback periods, supported by a cash reserve of 999 million yuan [8]. - A franchise model is also being considered, with plans to pilot 2 to 3 franchise stores later this year [9]. Market Outlook - The rapid growth of the light medical beauty market is attracting more participants, leading to increased competition, which poses ongoing challenges for New Oxygen [9].

Core Insights - The company is undergoing a significant transformation, facing structural challenges in the traditional internet medical beauty platform, as evidenced by a 7% year-over-year decline in total revenue to 379 million yuan and a net loss of 36 million yuan compared to a profit of 18.9 million yuan in the same period last year [1][3]. Revenue Performance - Total revenue for the first half of the year was 676 million yuan, down 6.9% year-over-year, with net losses widening to 67.95 million yuan from just 60,000 yuan in the same period last year [3]. - Revenue from information and appointment services, the company's core business, fell by 35.6% to 135 million yuan from 210 million yuan year-over-year, highlighting intense competition in the online medical beauty information service market [4]. - Revenue from medical product sales and maintenance services decreased by 28.1% to 76 million yuan from 106 million yuan year-over-year, reflecting a significant drop in order volume for medical beauty products [4]. Business Segment Analysis - The total transaction volume facilitated by the platform was 304 million yuan, down from 428 million yuan in the same period last year, indicating challenges in the traditional business sector [4]. - The offline chain business has seen explosive growth, with medical treatment service revenue increasing by 426.1% to 144 million yuan, becoming the largest revenue source for the company [5]. - As of June 30, the company operated 29 light medical beauty chain stores in major cities, with 25 stores achieving positive monthly operational cash flow, indicating a promising profitability outlook [5]. Strategic Initiatives - The company plans to expand the number of medical beauty centers to 50 by the end of 2025, with a long-term goal of reaching 1,000 stores within 8 to 10 years, reflecting management's confidence in the offline business strategy [5]. - The company is innovating its operational model by reducing drug and device distribution costs through centralized procurement and self-built product lines, achieving store efficiency rates 3 to 5 times higher than similar institutions [6].

Core Insights - The company reported a revenue of 676 million yuan (approximately 94.37 million USD) for the first half of 2025, a decrease of 6.9% compared to the same period last year [2] - The net loss for the first half of 2025 was 67.95 million yuan, compared to a net loss of 60,000 yuan in the same period last year [2] Q2 Financial Performance - The revenue for Q2 2025 was 379 million yuan (approximately 52.90 million USD), down 7% from 407 million yuan in the same quarter last year [5] - Medical aesthetic treatment service revenue in Q2 2025 was 144.4 million yuan (approximately 20.20 million USD), an increase of 426% from 27.4 million yuan year-over-year, driven by the expansion of brand medical aesthetic centers [5] - Information and appointment service revenue for Q2 2025 was 135.2 million yuan (approximately 18.90 million USD), a decrease of 35.6% from 209.7 million yuan year-over-year, primarily due to a reduction in the number of medical service providers subscribing to information services on the platform [5] - Sales of medical products and maintenance services in Q2 2025 were 76 million yuan (approximately 10.60 million USD), down 28.1% from 105.8 million yuan year-over-year, mainly due to a decline in medical product order volume [5] - Other service revenue in Q2 2025 was 23.2 million yuan (approximately 3.20 million USD), a decrease of 64.0% from 64.4 million yuan year-over-year, attributed to a reduction in premium service revenue [5] Profitability and Costs - Gross profit for Q2 2025 was 194 million yuan, with a gross margin of 51% [8] - Total expenses for Q2 2025 were 241.3 million yuan (approximately 33.70 million USD), a decrease of 1.8% from 245.6 million yuan year-over-year [11] - Sales and marketing expenses in Q2 2025 were 131.3 million yuan (approximately 18.30 million USD), down 0.7% from 132.3 million yuan year-over-year, mainly due to a reduction in wage costs [11] - General and administrative expenses were 78.8 million yuan, an increase of 11.3% from 70.8 million yuan year-over-year, driven by an increase in administrative staff to support business upgrades and new strategic initiatives [11] - R&D expenses were 31.2 million yuan, down 26.6% from 42.5 million yuan year-over-year, attributed to improved employee efficiency [11] Losses and Cash Position - Operating loss for Q2 2025 was 47.11 million yuan, compared to an operating profit of 6.72 million yuan in the same quarter last year, resulting in an operating margin of -12% [13] - The net loss for Q2 2025 was 34.80 million yuan, compared to a net profit of 20.12 million yuan in the same period last year [16] - As of June 30, 2025, the company held cash and cash equivalents, restricted cash, and short-term investments totaling 998.6 million yuan (approximately 139.4 million USD), down from 1.2532 billion yuan at the end of 2024 [17] Future Outlook - The company expects Q3 2025 revenue from beauty treatment services to be between 150 million yuan (approximately 20.90 million USD) and 170 million yuan (approximately 23.70 million USD), representing a year-over-year growth of 230.5% to 274.6% [17] - The company's stock price closed at 3.74 USD, down 22.73% from the previous day, with a market capitalization of 375 million USD [17]

Core Viewpoint - New Oxygen Technology is undergoing a significant strategic transformation amid a slowdown in online traffic and increasing regulation in the medical beauty industry, with a notable shift from online services to offline light medical beauty chain operations [1][2]. Financial Performance - In Q2, New Oxygen reported total revenue of 379 million yuan, a year-on-year decline of 7.0% [3]. - The company experienced a net loss of 36 million yuan in Q2, compared to a profit of 18.9 million yuan in the same period last year [4]. - Revenue from information and appointment services, a core business, fell by 35.6% to 135 million yuan, indicating intensified competition and regulatory pressures [3][4]. Business Transformation - New Oxygen's offline light medical beauty chain business saw a dramatic increase, with revenue soaring by 426.1% to 144 million yuan, becoming the largest revenue source for the company [1][5]. - The company aims to expand its "New Oxygen Youth Clinic" brand across major cities, with plans to increase the number of medical centers to 50 by the end of 2025 [6][7]. Market Position and Strategy - The management emphasizes the importance of standardization and product innovation to maintain market leadership in the light medical beauty sector [5]. - New Oxygen plans to adopt a mixed model of self-operated and franchised stores, with pilot franchise stores expected to launch in Q4 [7]. Future Outlook - The company has set a long-term goal of achieving a thousand-store scale within 8 to 10 years, reflecting confidence in the growth potential of the light medical beauty market [6][7]. - Despite the positive developments, New Oxygen faces challenges from increasing competition as more players enter the light medical beauty market [8].

Market Overview - US stock index futures showed mixed performance with Dow futures up by 0.59% and S&P 500 futures up by 0.12%, while Nasdaq futures declined by 0.05% [1] - European indices had varied results, with Germany's DAX up by 0.09%, UK's FTSE 100 down by 0.11%, France's CAC40 up by 0.58%, and the Euro Stoxx 50 up by 0.27% [2][3] - WTI crude oil prices fell by 0.53% to $63.62 per barrel, and Brent crude oil prices decreased by 0.39% to $66.58 per barrel [3][4] Geopolitical Events - A significant meeting is scheduled between US President Trump and Russian President Putin in Alaska, focusing on the Russia-Ukraine conflict and peace prospects, marking their first in-person meeting in four years [5] Federal Reserve Insights - Federal Reserve Chairman Powell is set to speak at the Jackson Hole conference on August 22, with market expectations leaning towards a potential 25 basis point rate cut due to inflation impacts and a slowing job market [6] - Bank of America strategist Hartnett warns that if the Fed signals a dovish stance at Jackson Hole, US stocks may face a "buy the rumor, sell the news" scenario [7] Hedge Fund Activity - Hedge funds have significantly increased their holdings in technology stocks during Q2, with notable purchases in Microsoft and Netflix, amidst a backdrop of market volatility due to trade policies [8] Economic Concerns - Bank of America raises alarms about the potential for the Fed to lower rates in a rising inflation environment, a scenario not seen in nearly two decades [9] Company Performance - Tuniu (TOUR.US) reported a 15.3% year-over-year revenue increase in Q2, with a new $10 million stock buyback plan announced [10] - New Oxygen (SY.US) experienced a 7.0% decline in Q2 revenue, attributed to a decrease in the number of medical service providers subscribing to its platform [11] - Applied Materials (AMAT.US) provided disappointing Q4 guidance, raising concerns about demand suppression due to US-China trade tensions [12] - Viomi Technology (VIOT.US) anticipates over 70% year-over-year revenue growth for the first half of 2025, driven by strong sales of home water purification devices [12]

Core Viewpoint - So-Young Technology reported a decline in total revenue and a net loss for the second quarter of 2024, highlighting challenges in the aesthetic medical services market while noting significant growth in its light medical beauty chain business [1][4]. Financial Performance - Total revenue for the second quarter was RMB 3.787 billion, down 7% from RMB 4.074 billion in the same period of 2024 [1]. - The net loss was RMB 360 million, compared to a net profit of RMB 189 million in the previous year [1]. - Adjusted net loss under Non-GAAP was RMB 305 million, compared to a net profit of RMB 222 million in 2024 [1]. Revenue Breakdown - Revenue from aesthetic treatment services reached RMB 1.444 billion, a significant increase of 426.1% year-over-year, driven by the expansion of brand medical beauty centers [3]. - Revenue from the sale of medical products and maintenance services was RMB 760 million, a decrease of 28.1% compared to RMB 1.058 billion in 2024, attributed to a reduction in order volume [4]. Operating Expenses - Total operating expenses for the second quarter were RMB 2.413 billion, a slight decrease of 1.8% from RMB 2.456 billion in the same quarter of 2024 [6]. - Research and development expenses were RMB 312 million, down 26.6% from RMB 425 million in the previous year [6]. Cash Position and Future Outlook - As of June 30, 2025, the company held cash and cash equivalents totaling RMB 9.986 billion, down from RMB 12.532 billion at the end of 2024 [8]. - For the third quarter of 2025, the company expects revenue from its light medical beauty chain business to reach between RMB 1.50 billion and RMB 1.70 billion, representing a year-over-year growth of 230.5% to 274.6% [8].

Financial Data and Key Metrics Changes - Total revenue for Q2 was RMB 379 million, a decrease of 7% year over year, primarily due to a decline in medical service providers subscribing to information services [15] - Aesthetic treatment service revenues reached RMB 144 million, an increase of 426% year over year, exceeding guidance [15] - Net loss attributable to the company was RMB 36 million, compared to a net income of RMB 18.9 million in the same period last year [19] - Non-GAAP net loss was RMB 30.5 million, compared to a non-GAAP net income of RMB 22.2 million in the same period of 2024 [19] - Basic and diluted losses per ADS were RMB 0.35, compared to earnings of RMB 0.18 in the same period last year [19] Business Line Data and Key Metrics Changes - Revenue from aesthetics center business reached RMB 144 million, marking it as the largest revenue segment for the first time [4] - Aesthetic treatment services revenue increased by 46% quarter over quarter and 426% year over year [5] - Total number of verified treatment visits surpassed 67,400 in Q2, up 24% quarter over quarter and 381% year over year [7] - The overall repeat purchase rate for the aesthetic center business exceeded 60% [7] Market Data and Key Metrics Changes - The light medical aesthetic market in China is expected to reach around RMB 26 billion by 2030, with a penetration rate forecasted to reach 30% [30] - The company aims to achieve a market share of roughly 25% in the light medical aesthetic sector [30] Company Strategy and Development Direction - The company plans to open around 10 aesthetic centers in the third quarter, targeting a total of 50 centers by year-end [11] - The focus is on expanding in both first-tier and core second-tier cities, enhancing accessibility to medical aesthetic services [11] - The company is committed to optimizing user experience and operational efficiency to strengthen its competitive edge [13] Management Comments on Operating Environment and Future Outlook - Management remains optimistic about the growth potential of China's medical aesthetic market, citing a current penetration rate below 5% [30] - The company expects aesthetic treatment service revenues to be between RMB 150 million and RMB 170 million in the upcoming quarter, representing a significant increase from the same period in 2024 [20] - The company emphasizes the importance of sustainable low-cost customer acquisition and a diversified upstream supply chain [31] Other Important Information - The company has maintained a robust cash position with cash and cash equivalents totaling RMB 98.6 million as of June 30, 2025 [20] - The gross profit margin for aesthetic treatment services expanded by around five percentage points sequentially [8] Q&A Session Summary Question: Expansion plan for C and I payment and franchise model - The company aims to grow the number of centers to 50 by the end of this year, with plans for more than 10 openings in the second half [24] - Long-term, the target is to achieve 1,000 centers within eight to ten years, with franchising being a future focus [25][26] Question: Growth potential of the Chinese medical aesthetics market - Management is optimistic about the market, with substantial growth potential indicated by a low current penetration rate [30] - The company plans to focus on three core capabilities to maintain its competitive edge [31] Question: Outlook for customer acquisition cost and marketing expenses - The average customer acquisition cost remains low, with over 70% of new customers coming from referrals [34] - The company plans to enhance brand visibility through localized marketing initiatives [34] Question: Recruitment of doctors and reliance on center managers - There is a solid base for recruiting doctors, with many moving from public hospitals to the medical aesthetic sector [40] - The company operates on a model that reduces reliance on center managers, improving operational efficiency [42] Question: Differentiation in product strategy - The product strategy focuses on anti-aging treatments, ensuring consistency and overall cost-effectiveness across the portfolio [46] - The company aims to optimize its product portfolio based on market demand and competitive trends [48] Question: Updates on the POP business - The POP business remains a key pillar of profitability, with plans to promote synergies between POP and aesthetic center businesses [50]